MOLECULAR BIOLOGICAL FACTORS OF PROGNOSIS AND EFFICIENCY OF MEDICAL TREATMENT FOR DISSEMINATED RENAL CELL CARCINOMA

Cover Page

Cite item

Full Text

Abstract

The substantial improvement of treatment results in patients with disseminated forms of renal cell carcinoma (RCC) is associated with the active clinical application of target drugs that affect the molecular genetic mechanisms underlying the development of this disease. Inactivation of the VHL gene and/or the disorders related to other elements of the signaling pathway regulating the processes of proliferation and neoangionesis in tumor tissue (mammalian target of rapamycin; hypoxia-induced factor; vascular endothelial growth factor and its receptor; platelet-derived growth factor receptor; and carboanhydrase IX) are considered to be one of the early and key events in carcinogenesis in clear cell RCC. However, there is presently no consensus of opinion as the prognostic value of these disorders and their impact on the efficiency of drug therapy. The results of the clinical trials assessing potential molecular biological markers are discordant. This is attributable both to the dissimilar clinical characteristics of patients and different methodological approaches to evaluating these or those molecular impairments. There are also other alternative signaling pathways and mechanisms responsible for the formation of primary or secondary drug resistance when target agents are administered. Thus, the quest of potential biomarkers remains an urgent problem as before. This paper analyzes the results of the currently available clinical studies of the role of various biological markers in predicting the efficiency of the present-day medicinal approaches to treating patients with RCC.

About the authors

D. A. Nosov

Department of Clinical Pharmacology and Chemotherapy

Author for correspondence.
Email: nosov@mail.ru
Russian Federation

E. S. Yakovleva

Department of Clinical Pharmacology and Chemotherapy

Email: nosov@mail.ru
Russian Federation

D. A. Atayeva

Department of Clinical Pharmacology and Chemotherapy

Email: nosov@mail.ru
Russian Federation

L. N. Lyubchenko

Laboratory of Clinical Oncogenetics, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow

Email: nosov@mail.ru
Russian Federation

S. A. Tyulyandin

Department of Clinical Pharmacology and Chemotherapy

Email: nosov@mail.ru
Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.